



# Supplementary Materials: Per-Feature Accuracy of Liver Imaging Reporting and Data System Locoregional Treatment Response Algorithm: A Systematic Review and Meta-Analysis


Yeon Jong Huh, Dong Hwan Kim, Bohyun Kim, Joon-Il Choi and Sung Eun Rha



**Figure S1.** Results of quality assessments of the articles according to QUADAS-2 criteria. The methodological quality distribution of the articles is presented as the proportions of articles (0–100%) with a low (i.e., high quality), high, and unclear risk of bias and the proportions of articles with low (i.e., high quality), high, or unclear concerns regarding applicability for each domain.



**Figure S2.** Hierarchical summary receiver operating characteristic curves for the accuracy of arterial phase hyperenhancement (a), washout appearance (b), or enhancement similar to pretreatment (c).



**Figure S3.** Deeks' funnel plot to evaluate publication bias regarding arterial phase hyperenhancement (a), washout appearance (b), or enhancement similar to pretreatment (c).

**Table S1.** Search queries.

No.	Search Queries for MEDLINE
#1	("Liver Neoplasms"[Mesh] OR "Liver"[Mesh]) AND "Radiology Information Systems"[mesh]
#2	"LI-RADS"[TW] OR "LR-TR"[TW] OR "liver imaging reporting"[TW] OR "LI-RADS Treatment Response"[TW]
#3	#1 OR #2
#4	Magnetic Resonanc*[TW] OR MRI[TW] OR MR[TW] OR CT[TW] OR Computed Tomography[TW]
#5	#3 AND #4
#6	#5 AND English[Lang] AND ("2017/01/01"[PDAT]: "3000/12/31"[PDAT])
No.	Search queries for EMBASE
#1	'liver imaging reporting and data system'/exp
#2	('LI-RADS' OR 'LR-TR' OR 'liver imaging reporting' OR 'LI-RADS Treatment Response'):ab,ti,kw
#3	#1 OR #2
#4	('Magnetic Resonanc*' OR MRI OR MR OR CT OR 'Computed Tomography'):ab,ti,kw
#5	#3 AND #4
#6	#5 AND [english]/lim AND [2017-2021]/py

**Table S2.** Numbers of true positives, false positives, false negatives, and true negatives of each imaging feature of LR-TR viable category for diagnosing viable HCC.

Imaging Feature	Author (Publication Year)	Total Number of Observations	Number of Observations			
			TP	FP	FN	TN
NMLIT with APHE	Saleh TY (2019)	40	19	1	0	20
	Kim SW (2020)	183	81	31	3	68
	Seo N (2020)	84	41	3	17	23
	Park S (2020)	138	78	5	30	25
	Bae JS (2021)	237	56	7	51	123
	Granata V (2021)	136	21	0	2	113
	Huh J (2021)	151	34	2	33	82
	Mahmoud BE (2021)	45	14	2	0	29
	Yoon J (2021)	34	14	0	5	15
	Youn SY (2021)	105	35	1	38	31
NMLIT with washout appearance	Kim SW (2020)	183	57	7	27	92
	Seo N (2020)	84	26	2	32	24
	Park S (2020)	138	77	2	31	28
	Bae JS (2021)	237	42	4	65	126
	Granata V (2021)	136	23	3	0	110
	Huh J (2021)	151	11	1	56	83
	Yoon J (2021)	34	8	0	11	15
	Youn SY (2021)	105	34	1	39	31
NMLIT with enhancement similar to pre-treatment	Seo N (2020)	84	8	0	50	26
	Park S (2020)	98	57	2	23	16
	Bae JS (2021)	237	26	4	81	126
	Huh J (2021)	151	0	0	67	84
	Yoon J (2021)	34	8	0	11	15
	Youn SY (2021)	105	23	1	50	31

LR-TR, Liver Imaging Reporting and Data System treatment response; HCC, hepatocellular carcinoma; NMLIT, nodular, mass-like, or irregular thick tissue in or along the treated lesion; APHE, arterial phase hyperenhancement; TP, true positive; FP, false positive; FN, false negative; TN, true negative.